Sanofi Announces Call for Submissions for Ignite: The Diabetes Ideas Challenge
PARIS, Apr. 16, 2013 /PRN=KYODO JBN/ --
- Worldwide invitation to create and submit concepts for a potential
next-generation insulin delivery device
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that it is accepting
submissions for Ignite: The Diabetes Ideas Challenge ("Ignite Challenge"). The
web-based Ignite Challenge invites patients, caregivers, designers, engineers,
and innovators from around the globe to submit ideas that could shape the
features and design of a next-generation, insulin delivery device for people
with diabetes. Building on the user experience and technology advances of the
past 30 years, the Ignite Challenge seeks to address the critical need for
innovative, easy-to-use and cost-effective devices for delivering injectable
medications for the treatment of diabetes.
"Over time and across geographies, we observe a consistent increase in the
use of injectable medications among the more than 370 million people living
with diabetes," said Pierre Chancel, Senior Vice President, Global Diabetes,
Sanofi. "Through innovation challenges such as the Ignite Challenge, Sanofi
hopes to foster creative thinking and new ideas that may improve the way people
manage their diabetes in the future using patient-friendly and innovative
Many people living with diabetes use insulin and an insulin delivery device
as part of their overall treatment plan, which may include other medications,
along with a healthy diet and exercise. The Ignite Challenge turns to
innovators to submit ideas that may advance the technology and design of
today's insulin delivery devices, while maintaining key factors including
reliability, ease of use and aesthetic appeal. The Ignite Challenge will award
ten winning submissions $5,000 each for their original ideas.
Challenge concept submissions must meet the following three criteria:
Accessibility - concept must be usable by a broad population, including the
young and old, or people with impaired hand use or vision.
Appropriateness - concept must be easy to integrate into daily life and be of
high quality. Device should be portable and aesthetically pleasing. It has to
be recognizable as an injection device, while not appearing overtly medical.
Functionality - Device must meet functional requirements as a medical tool,
should enable accurate delivery, have functionality for extended periods
without electricity, and the ability to store more than one dose of insulin per
"Sanofi understands the importance of going beyond the molecule to help
people manage the complex challenges of diabetes," said Christoph Heinemann,
Vice President Strategy and Portfolio Management, Global Diabetes, Sanofi.
"While we are committed to our current and award-winning insulin delivery
device offerings, we understand the importance of exploring new, innovative
approaches that may take years to develop and test but that could provide
additional offerings to people living with diabetes."
Over the past few years, innovation challenges have become an integral part
of Sanofi's commitment to diabetes care. This year marks the company's third
annual Data Design Diabetes(TM) Innovation Challenge in the U.S., which has a
three-part aim: innovation in the quality, delivery, and cost of diabetes care.
Sanofi U.S. also developed the Partners in Patient Health Collaborate -
Activate Innovation Challenge in 2012, which awarded teams that delivered novel
approaches to better engage patients in healthcare. The Ignite Challenge
continues this momentum by encouraging the development of solutions that show
potential to directly meet patients' needs.
The full timeline for the Ignite Challenge is as follows:
Open Submissions: April 8 - May 10
The Ignite Challenge website [http://www.igniteideaschallenge.com/ ] is open
for submissions and will remain open until May 10, 2013.
Submission Review and Judging: May 13 - May 24
An expert panel of judges will review the Ignite Challenge submissions.
Winner Announcements: May 30
Ten winners will be announced and each awarded $5,000.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including intelligent blood glucose monitoring
systems. Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
This press release contains forward-looking statements. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding
labelling and other matters that could affect the availability or commercial
potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group's ability to benefit
from external growth opportunities, trends in exchange rates and prevailing
interest rates, the impact of cost containment policies and subsequent changes
thereto, the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2012. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any forward-looking
information or statements.
SOURCE: Sanofi Diabetes